Inhibition of TXNIP expression in vivo blocks early pathologies of diabetic retinopathy

Cell Death and Disease

Volumn 1, Issue 8, 2010, Pages

  Perrone, L ^a,b   Devi, T S ^a   Hosoya, K I ^c   Terasaki, T ^d   Singh, L P ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CNRS   (France)

^c UNIVERSITY OF TOYAMA   (Japan)

^d TOHOKU UNIVERSITY   (Japan)

Author keywords

DR; Gliosis; HBP; Inflammation; TGS; TXNIP

Indexed keywords

CYCLOOXYGENASE 2; FIBRONECTIN; HEXOSAMINE; MESSENGER RNA; SMALL INTERFERING RNA; THIOREDOXIN INTERACTING PROTEIN; CARRIER PROTEIN; GLUCOSE; PTGS2 PROTEIN, RAT; TXNIP PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC RETINOPATHY; GENE SILENCING; GLIOSIS; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RETINA; ANIMAL; BIOLOGICAL MODEL; CELL CULTURE; DRUG EFFECT; ENDOTHELIUM CELL; ENZYMOLOGY; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INFLAMMATION; METABOLISM; PATHOLOGY;

RATTUS;

ANIMALS; BIOSYNTHETIC PATHWAYS; CARRIER PROTEINS; CELLS, CULTURED; CYCLOOXYGENASE 2; DIABETIC RETINOPATHY; ENDOTHELIAL CELLS; FIBRONECTINS; FIBROSIS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE SILENCING; GLIOSIS; GLUCOSE; HEXOSAMINES; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; RATS; RETINA; RNA, MESSENGER;

EID: 79958859597     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2010.42     Document Type: Article

References (40)

1. Congdon N, O'Colmain B, Klaver CC, Klein R, Muñoz B, Friedman DS et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004;122:477-485. (Pubitemid 38456282)
2. Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, Jefferson LS et al. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 2006;55:2401-2411. (Pubitemid 44871140)
3. Khan ZA, Chan BM, Uniyal S, Barbin YP, Farhangkhoee H, Chen S et al. EDB fibronectin and angiogenesis - a novel mechanistic pathway. Angiogenesis 2005;8:183-196. (Pubitemid 41759143)
4. Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 2006;55:1463-1469. (Pubitemid 44195388)
5. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res 2007;2007:95103.
6. Junn E, Han S, Im J, Yang Y, Cho E, Um H et al. Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J Immunol 2000;164:6287-6295. (Pubitemid 30408809)
7. Hui ST, Andres AM, Miller AK, Spann NJ, Potter DW, Post NM et al. Txnip balances metabolic and growth signaling via PTEN disulfide reduction. Proc Natl Acad Sci USA 2008;105:3921-3926. (Pubitemid 351723500)
8. Chen J, Hui ST, Couto FM, Mungrue IN, Davis DB, Attie AD et al. Thioredoxin-interacting protein deficiency induces Akt/Bcl-xL signaling and pancreatic beta-cell mass and protects against diabetes. FASEB J 2008;22:3581-3594.
9. Chen J, Saxena G, Mungrue IN, Lusis AJ, Shalev A. Thioredoxin-interacting protein: a critical link between glucose toxicity and beta-cell apoptosis. Diabetes 2008;57:938-1044.
10. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010;11:136-140.
11. Cheng DW, Jiang Y, Shalev A, Kowluru R, Crook ED, Singh LP. An analysis of high glucose and glucosamine-induced gene expression and oxidative stress in renal mesangial cells. Arch Physiol Biochem 2006;112:189-218. (Pubitemid 46018362)
12. Hamada Y, Fukagawa M. A possible role of thioredoxin interacting protein in the pathogenesis of streptozotocin-induced diabetic nephropathy. Kobe J Med Sci 2007;53:53-61. (Pubitemid 47041682)
13. Price SA, Gardiner NJ, Duran-Jimenez B, Zeef LA, Obrosova IG, Tomlinson DR. Thioredoxin interacting protein is increased in sensory neurons in experimental diabetes. Brain Res 2006;1116:206-214. (Pubitemid 44488597)
14. Perrone L, Devi TS, Hosoya KI, Terasaki T, Singh LP. Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions. J Cell Physiol 2009;221:262-272.
15. Singh L, Andy J, Anyamale V, Greene K, Alexander M, Crook ED. Hexosamine-induced fibronectin protein synthesis in mesangial cells is associated with increases in cAMP responsive element binding (CREB) phosphorylation and nuclear CREB: the involvement of protein kinases A and C. Diabetes 2001;50:2355-2362. (Pubitemid 33641923)
16. Singh LP, Cheng D, Kowluru RA, Levi E, Jiang Y. Hexosamine induction of oxidative stress, hypertrophy and laminin expression in renal mesangial cells: effect of the antioxidant alpha-lipoic acid. Cell Biochem Funct 2007;25:537-550. (Pubitemid 47436095)
17. Cherney DZ, Miller JA, Scholey JW, Bradley TJ, Slorach C, Curtis JR et al. The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes. Diabetes 2008;5:688-695.
18. Mette MF, Aufsatz W, van der Winden J, Matzke MA, Matzke AJ. Transcriptional silencing and promoter methylation triggered by double-stranded RNA. EMBO J 2000;19:5194-5201.
19. Morris KV, Chan SW, Jacobsen SE, Looney DJ. Small interfering RNA-induced transcriptional gene silencing in human cells. Science 2004;305:1289-1292. (Pubitemid 39129233)
20. Miao F, Wu X, Zhang L, Yuan YC, Riggs AD, Natarajan R. Genome-wide analysis of histone lysine methylation variations caused by diabetic conditions in human monocytes. J Biol Chem 2007;282:13854-13863. (Pubitemid 47100501)
21. Mönkemann H, De Vriese AS, Blom HJ, Kluijtmans LA, Heil SG, Schild HH et al. Early molecular events in the development of the diabetic cardiomyopathy. Amino Acids 2002;23:331-336.
22. Chen S, Feng B, George B, Chakrabart R, Chen M, Chakrabarti S. Transcriptional co-activator p300 regulates glucose induced gene expression in the endothelial cells. Am J Physiol Endocrinol Metab 2010;298:E127-E137.
23. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003;9:294-299. (Pubitemid 36362784)
24. Marchetti V, Menghini R, Rizza S, Vivanti A, Feccia T, Lauro D et al. Benfotiamine counteracts glucose toxicity effects on endothelial progenitor cell differentiation via Akt/FoxO signaling. Diabetes 2006;55:2231-2237. (Pubitemid 44743619)
25. Du X, Edelstein D, Brownlee M. Oral benfotiamine plus alpha-lipoic acid normalises complication-causing pathways in type 1 diabetes. Diabetologia 2008;51:1930-1932.
26. Al-Mubarak B, Soriano FX, Hardingham GE. Synaptic NMDAR activity suppresses FOXO1 expression via a cis-acting FOXO binding site: FOXO1 is a FOXO target gene. Channels (Austin) 2009;3:233-238.
27. George B, Chen S, Chaudhary V, Gonder J, Chakrabarti S. Extracellular matrix proteins in epiretinal membranes and in diabetic retinopathy. Curr Eye Res 2009;34:134-144.
28. Lappalainen Z, Lappalainen J, Oksala NK, Laaksonen DE, Khanna S, Sen CK et al. Diabetes impairs exercise training-associated thioredoxin response and glutathione status in rat brain. J Appl Physiol 2009;106:461-467.
29. Munemasa Y, Ahn JH, Kwong JM, Caprioli J, Piri N. Redox proteins thioredoxin 1 and thioredoxin 2 support retinal ganglion cell survival in experimental glaucoma. Gene Ther 2009;16:17-25.
30. Morris KV. The antisense strand of small interfering RNAs directs histone methylation and transcriptional gene silencing in human cells. RNA 2006;12:256-262. (Pubitemid 43121930)
31. Morris KV. Long antisense non-coding RNAs function to direct epigenetic complexes that regulate transcription in human cells. Epigenetics 2009;4:296-301.
32. Johnson LN, Cashman SM, Kumar-Singh R. Cell-penetrating peptide for enhanced delivery of nucleic acids and drugs to ocular tissues including retina and cornea. Mol Ther 2008;6:107-114.
33. Wang MH, Frishman LJ, Otteson DC. Intracellular delivery of proteins into mouse Müller glial cells in vitro and in vivo using Pep-1 transfection reagent. J Neurosci Methods 2009;177:403-419.
34. Kaimul AM, Nakamura H, Masutani H, Yodoi J. Thioredoxin and thioredoxin-binding protein-2 in cancer and metabolic syndrome. Free Radic Biol Med 2007;43:861-868. (Pubitemid 47223630)
35. Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger? Science 2010;327:296-300.
36. Chan PS, Kanwar M, Kowluru RA. Resistance of retinal inflammatory mediators to suppress after reinstitution of good glycemic control: novel mechanism for metabolic memory. J Diabetes Complicat 2010;24:55-63.
37. Lim HG, Suzuki K, Cooper DA, Kelleher AD. Promoter-targeted siRNAs induce gene silencing of simian immunodeficiency virus (SIV) infection in vitro. Mol Ther 2008;16:565-570. (Pubitemid 351314997)
38. Suzuki K, Juelich T, Lim H, Ishida T, Watanebe T, Cooper DA et al. Closed chromatin architecture is induced by an RNA duplex targeting the HIV-1 promoter region. J Biol Chem 2008;283:23353-23363.
39. Morris MC, Deshayes S, Heitz F, Divita G. Cell-penetrating peptides: from molecular mechanisms to therapeutics. Biol Cell 2008;100:201-217. (Pubitemid 351517084)
40. Ivanova E, Pan ZH. Evaluation of the adeno-associated virus mediated long-term expression of channelrhodopsin-2 in the mouse retina. Mol Vis 2009;15:1680-1689.